首页> 外文期刊>Cell cycle >PARP3 comes to light as a prime target in cancer therapy
【24h】

PARP3 comes to light as a prime target in cancer therapy

机译:PARP3作为癌症治疗中的主要目标

获取原文
获取原文并翻译 | 示例
       

摘要

Poly(ADP-ribose) polymerase 3 (PARP3) is the third member of the PARP family that catalyze a post-translational modification of proteins to promote, control or adjust numerous cellular events including genome integrity, transcription, differentiation, cell metabolism or cell death. In the late years, PARP3 has been specified for its primary functions in programmed and stress-induced double-strand break repair, chromosomal rearrangements, transcriptional regulation in the zebrafish and mitotic segregation. Still, deciphering the therapeutic value of its inhibition awaits additional investigations. In this review, we discuss the newest advancements on the specific functions of PARP3 in cancer aggressiveness exemplifying the relevance of its selective inhibition for cancer therapy.
机译:聚(ADP-核糖)聚合酶3(PARP3)是PARP系列的第三个成员,其催化蛋白质的翻译后修饰,以促进,控制或调节多种细胞事件,包括基因组完整性,转录,分化,细胞代谢或细胞死亡 。 在晚期,PARP3已被规定为其编程和应力诱导的双链断裂修复,染色体重排,斑马鱼和有丝分裂偏析的转录调节的主要功能。 尽管如此,解密其抑制的治疗价值等待额外的调查。 在本综述中,我们讨论了对PARP3在癌症侵略性中的特定功能的最新进展,示出了其对癌症治疗的选择性抑制的相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号